{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:39:00Z","timestamp":1755034740151,"version":"3.37.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"36","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020","award":["759248"],"award-info":[{"award-number":["759248"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004807","name":"DFG","doi-asserted-by":"publisher","award":["SFB834 B12","75732319"],"award-info":[{"award-number":["SFB834 B12","75732319"]}],"id":[{"id":"10.13039\/100004807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"DOI":"10.1093\/eurheartj\/ehab427","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:06:21Z","timestamp":1624993581000},"page":"3783-3785","source":"Crossref","is-referenced-by-count":8,"title":["Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-7175","authenticated-orcid":false,"given":"Simon","family":"Tual-Chalot","sequence":"first","affiliation":[{"name":"Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University , Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-0825","authenticated-orcid":false,"given":"Konstantinos","family":"Stellos","sequence":"additional","affiliation":[{"name":"Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University , Newcastle Upon Tyne, UK"},{"name":"Department of Cardiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"2022102708181385600_ehab427-B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2022102708181385600_ehab427-B2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0195-668X(02)00829-1","article-title":"Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy","volume":"24","author":"Lips","year":"2003","journal-title":"Eur Heart J"},{"key":"2022102708181385600_ehab427-B3","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(98)00407-0","article-title":"Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death","volume":"32","author":"Haider","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022102708181385600_ehab427-B4","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1038\/s41467-018-06639-7","article-title":"Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure","volume":"9","author":"Nomura","year":"2018","journal-title":"Nat Commun"},{"key":"2022102708181385600_ehab427-B5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension"},{"key":"2022102708181385600_ehab427-B6","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab347","article-title":"Neuraminidase 1 is a driver of experimental cardiac hypertrophy","volume":"42","author":"Chen","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102708181385600_ehab427-B7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00395-020-00821-z","article-title":"Neuraminidase-1 promotes heart failure after ischemia\/reperfusion injury by affecting cardiomyocytes and invading monocytes\/macrophages","volume":"115","author":"Heimerl","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"2022102708181385600_ehab427-B8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.031139","article-title":"Functional metabolomics characterises a key role for N-acetylneuraminic acid in coronary artery diseases","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2022102708181385600_ehab427-B9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cardiores.2004.03.025","article-title":"GATA transcription factors in the developing and adult heart","volume":"63","author":"Pikkarainen","year":"2004","journal-title":"Cardiovasc Res"},{"key":"2022102708181385600_ehab427-B10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/science.aay0678","article-title":"Broadly protective human antibodies that target the active site of influenza virus neuraminidase","volume":"366","author":"Stadlbauer","year":"2019","journal-title":"Science"},{"key":"2022102708181385600_ehab427-B11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2022102708181385600_ehab427-B12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19\u2014interim WHO Solidarity Trial Results","volume":"384","author":"Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102708181385600_ehab427-B13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102708181385600_ehab427-B14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/21678707.2015.1025746","article-title":"Pathogenesis, emerging therapeutic targets and treatment in sialidosis","volume":"3","author":"d\u2019Azzo","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"2022102708181385600_ehab427-B15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCOUTCOMES.108.820357","article-title":"Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases","volume":"2","author":"Casscells","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3783\/46650611\/ehab427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3783\/46650611\/ehab427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:18:44Z","timestamp":1666858724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3783\/6319852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":15,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021,7,13]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab427","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2021,9,21]]},"published":{"date-parts":[[2021,7,13]]}}}